Небиеридзе Д. В. Комбинированная терапия артериальной гипертонии: фокус на плейотропные эффекты. Кардиоваскулярная терапия и профилактика. 2007;6(4):99-102.
1. Второй пересмотр рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваск тер профил 2004; 3(3) ч.1: 105-20.
2. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfined randomized drug trials in an epidemiological context. Lancet 1990; 335: 827-38.
3. HOPE study investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
4. Estasio RO, Jeffers BW, Hiatt W, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ABCD Study. N Eng J Med 1998; 338: 645-52.
5. Kaplan M. Metabolic Aspects of Hypertension. Science press 1994, London.
6. Pepine CJ, Handberg EM, Cooper RM, at al. A Calcium Antagonist vs a Non-Calcium Antagonist Hypertension Tretment Strategy for Patients With Coronary Artery Disease The International Verapamil SR/Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA 2003; 290(21): 2805-61.
7. The ALLHAT Officers and Coordinators Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97.
8. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
9. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension 2003. Guidelines Committee. J Hypertens 2003; 21: 1011-53.
10. Fernandez R, Puig JG, Rodrigues-Perez JC, et al. Effect of two antihypertensive combinations on metabolic control in type -2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Human Hypertens 2001; 15: 849-56.
11. Bakris G, Molitch M, Hewkin A, et al. Differences in Glucose tolerance between fixed dose Antihypertensive Drug Combinations in People with Metabolic Syndrome. Diabetes Care 2006; 29: 2592-7.
12. Zanchetti A, Rosei EA, Palu CD, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.
13. Hansen JF, Hageruo L, Sigurd B. Cardiac Event Rates After Acute Myocardial Infarction in Patients Treated With Verapamil and Trandolapril Versus Trandolapril Alone, et al. Am J Cardiol 1997; 79: 738-41.
14. Ruggenenti P, Fassi A, Parvanova Ilieva A, et al. Preventing microalbuminuria in Type 2 Diabetes. N Engl J Med 2004; 351: 1941-51.
